Skip to content

Needle Guiding Robot for Radiofrequency Ablation: Safety and Efficacy Study on Hepatocellular Carcinoma Patients

Single Center and Exploratory Investigator-initiated Trial to Evaluate the Safety and Efficacy of Needle Guiding Robot System for Radiofrequency Ablation in Hepatocellular Carcinoma Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03005756
Acronym
NGR
Enrollment
20
Registered
2016-12-29
Start date
2017-01-25
Completion date
2019-03-31
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Hepatocellular

Brief summary

The needle guiding robot helps targeting of radiofrequency ablation needles by matching computed tomography images and patients' bodies. Actual insertion of needles will be performed by doctors. This study evaluates the safety and efficacy of needle targeting on patients with hepatocellular carcinoma.

Detailed description

A robotic system has been developed that includes a needle-path planning system and a needle-guiding robot arm with computed tomography (CT) guidance. The robot consists of robot base, 5-axis robot arm with guiding end-effector and path-planner. Optical tracking system with a custom-designed registration jig is used for the spatial registration and validation. Advantages of the robotic system would be accurate targeting with diverse angulation of the robot arm in CT-guided tumor ablation. Furthermore, robotic intervention might potentially decrease procedure time and radiation exposure to patients. The purpose of this clinical trial with patients with hepatocelluar carcinoma is to assess the safety and efficacy of our CT-guided needle-guiding robot.

Interventions

DEVICENeedle guiding robot

This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.

Sponsors

Ministry of Health & Welfare, Korea
CollaboratorOTHER_GOV
Hyundai Heavy Industries
CollaboratorUNKNOWN
Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with up to three Hepatocellular carcinomas (HCC) with no single HCC larger than 3 cm * Candidates for CT-guided radiofrequency ablation of HCC * Child-Pugh class A or B

Exclusion criteria

* Patients with untreatable/unmanageable coagulopathy * Patients who are allergic to CT contrast media * Patients with vascular invasion or extrahepatic metastases

Design outcomes

Primary

MeasureTime frameDescription
Total radiation exposure (DLP, mGy*cm)At time of radiofrequency ablationSum of radiation exposures measured during the radiofrequency ablation

Secondary

MeasureTime frameDescription
Procedure timeAt time of radiofrequency ablationTotal period of time from the installation of needle guiding robot to patient's transfer after the procedure
Number of repositioning of radiofrequency electrodeAt time of radiofrequency ablationNumber of repositioning of radiofrequency electrode in order to correct targeting discrepancy untile properly placed in to the target tumor
Targeting errorAt time of the 1st insertion of the electrodeDistance between the target and the electrode tip

Countries

South Korea

Contacts

Primary ContactSang Do Lee, MD, PhD
webmaster@amc.seoul.kr82-2-3010-3013

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026